Inclusion Criteria:

• Patients who have a single or multiple de novo coronary artery lesion with 70% stenosis intended to be treated by PTCA using balloons, laser or atherectomy devices plus stent insertion.
• Patients with stable angina pectoris or unstable angina pectoris
• Patients must have veins with adequate access for photopheresis.

-Patients must not be pregnant Female patients who are in child- bearing years and have not been surgically sterilized will be tested for pregnancy by a serum HCG test prior to enrollment into the study and must agree to practice contraception during her participation in the study.

• Patients must be willing to return for evaluation every two weeks and for all photopheresis treatments if in Groups 2, 3.
• Patients must sign an informed consent form prior to entry into the study.
• Patients must live within commuting distance of the treatment center.
• Patients must not be treated with any other investigational drug or device within 6 months prior to participation in this study.

Angiographic Inclusion Criteria:

-Patients who have a single or multiple de novo coronary artery lesion with 70% stenosis successfully treated by PTCA plus stent insertion to <50% stenosis as documented by on-line quantitative coronary angiography (QCA).

General Exclusion Criteria:

• Patients who cannot tolerate extracorporeal volume loss during the leukocyte enrichment phase.
• Patients with photosensitive disease, such as porphyria or systemic lupus erythematous. Care must be taken in selecting patients who require drugs either topically or systemically during the course of the study with photosensitizing potential, such as phenothiazine, tetracycline, sulfonamides or chlorothiazide. Patients who must take photosensitizing drugs will not receive them prior to each photopheresis treatment.
• Patients with renal insufficiency (creatinine >3.0 mg/dl).
• Patients who are pregnant or nursing a child.
• Patients with a severe coexisting medical, physiological or sociological condition that in the opinion of the investigators would preclude any of the procedures contained in this protocol.
• Patients who exhibit idiosyncratic or hypersensitivity reactions to psoralen compounds.
• Patients with a platelet count < 50,000/mm.
• Patients with active hepatitis.
• Patients with hemoglobin < 9 or hematocrit <27.
• Patients under age 18.
• Patients with ostial lesions.
• Patients who are insulin-dependent diabetics.
• Patients who have had an acute myocardial infarction within the previous 8 weeks. is (CCS Class 1, 2, or 4 and Braunwald Class 1-3, B-C) or document silent ischemia.
• Patents must have evidence of left ventricular ejection fraction of >30%.
• Patients must have a hematocrit >27 and hemoglobin >9.
• Patients must be at least 18 years of age.